PortalPublikationenNeuroprotektive Ansätze

Neuroprotektive Ansätze

Standard

Neuroprotektive Ansätze. / Thaler, S; Haritoglou, C; Schuettauf, F.

in: OPHTHALMOLOGE, Jahrgang 110, Nr. 10, 10.2013, S. 941-7.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Thaler, S, Haritoglou, C & Schuettauf, F 2013, 'Neuroprotektive Ansätze', OPHTHALMOLOGE, Jg. 110, Nr. 10, S. 941-7. https://doi.org/10.1007/s00347-013-2831-0

APA

Thaler, S., Haritoglou, C., & Schuettauf, F. (2013). Neuroprotektive Ansätze. OPHTHALMOLOGE, 110(10), 941-7. https://doi.org/10.1007/s00347-013-2831-0

Vancouver

Thaler S, Haritoglou C, Schuettauf F. Neuroprotektive Ansätze. OPHTHALMOLOGE. 2013 Okt;110(10):941-7. https://doi.org/10.1007/s00347-013-2831-0

Bibtex

@article{4776e685d4d64c458e4e4856f96d4501,
title = "Neuroprotektive Ans{\"a}tze",
abstract = "After introduction of vitreoretinal surgery more than 40 years ago, further development of the procedure involved a continuous reduction of potential toxic effects by irrigating solutions, endoillumination or mechanical manipulation. Recently, additional efforts were made to prevent neurodegeneration via pharmacological intervention. Taurine as additive for irrigating solutions can be considered as an example for neuroprotectants in vitreoretinal surgery. Approval of neuroprotective agents demands an increased effort for preclinical and clinical evaluation. To date, only few neuroprotective substances are used in clinical routine in the context of vitreoretinal surgery, however, experimental data suggest a high potential of various neuroprotective agents. The following article gives an overview of current neuroprotective approaches feasible for vitreoretinal surgery and a critical analysis of their clinical relevance. ",
keywords = "Humans, Intravitreal Injections, Neuroprotective Agents/administration & dosage, Ophthalmic Solutions/administration & dosage, Postoperative Complications/etiology, Premedication/methods, Retinal Diseases/surgery, Taurine/administration & dosage, Vitreoretinal Surgery/adverse effects",
author = "S Thaler and C Haritoglou and F Schuettauf",
year = "2013",
month = oct,
doi = "10.1007/s00347-013-2831-0",
language = "Deutsch",
volume = "110",
pages = "941--7",
journal = "OPHTHALMOLOGE",
issn = "0941-293X",
publisher = "Springer",
number = "10",

}

RIS

TY - JOUR

T1 - Neuroprotektive Ansätze

AU - Thaler, S

AU - Haritoglou, C

AU - Schuettauf, F

PY - 2013/10

Y1 - 2013/10

N2 - After introduction of vitreoretinal surgery more than 40 years ago, further development of the procedure involved a continuous reduction of potential toxic effects by irrigating solutions, endoillumination or mechanical manipulation. Recently, additional efforts were made to prevent neurodegeneration via pharmacological intervention. Taurine as additive for irrigating solutions can be considered as an example for neuroprotectants in vitreoretinal surgery. Approval of neuroprotective agents demands an increased effort for preclinical and clinical evaluation. To date, only few neuroprotective substances are used in clinical routine in the context of vitreoretinal surgery, however, experimental data suggest a high potential of various neuroprotective agents. The following article gives an overview of current neuroprotective approaches feasible for vitreoretinal surgery and a critical analysis of their clinical relevance.

AB - After introduction of vitreoretinal surgery more than 40 years ago, further development of the procedure involved a continuous reduction of potential toxic effects by irrigating solutions, endoillumination or mechanical manipulation. Recently, additional efforts were made to prevent neurodegeneration via pharmacological intervention. Taurine as additive for irrigating solutions can be considered as an example for neuroprotectants in vitreoretinal surgery. Approval of neuroprotective agents demands an increased effort for preclinical and clinical evaluation. To date, only few neuroprotective substances are used in clinical routine in the context of vitreoretinal surgery, however, experimental data suggest a high potential of various neuroprotective agents. The following article gives an overview of current neuroprotective approaches feasible for vitreoretinal surgery and a critical analysis of their clinical relevance.

KW - Humans

KW - Intravitreal Injections

KW - Neuroprotective Agents/administration & dosage

KW - Ophthalmic Solutions/administration & dosage

KW - Postoperative Complications/etiology

KW - Premedication/methods

KW - Retinal Diseases/surgery

KW - Taurine/administration & dosage

KW - Vitreoretinal Surgery/adverse effects

U2 - 10.1007/s00347-013-2831-0

DO - 10.1007/s00347-013-2831-0

M3 - SCORING: Review

C2 - 24046168

VL - 110

SP - 941

EP - 947

JO - OPHTHALMOLOGE

JF - OPHTHALMOLOGE

SN - 0941-293X

IS - 10

ER -